ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning CapabilityNewest version of award-winning software enables life sciences companies to conduct fast, accurate, and flexible clinical trial planning at the portfolio or program level Chicago, IL – March 3, 2009 – ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that it has released version 2.7 of its market-leading ClearTrial clinical trial software, which helps biopharmaceutical companies and clinical research organizations (CROs) accelerate and improve the planning and execution of their clinical trials. Today, 6 of the top 10 biotech companies and many of the largest companies in the industry rely on ClearTrial software to bring quality treatments to market faster, with less cost and effort. With ClearTrial Portfolio Planning, available in the Enterprise Edition of ClearTrial v2.7, clinical development organizations can now roll up protocol-level study plans into portfolio-level forecasts in minutes, providing instant visibility to monthly budgets, monthly resource demand, and timelines across a program, business unit, therapeutic indication, region, service provider or any other dimension – a capability unique to the industry. And when protocol-level assumptions change, the software automatically updates the portfolio forecast in seconds.
"ClearTrial Portfolio Planning gives life sciences companies a lightning-fast and more informed portfolio and program decision-making capability that presents a major competitive advantage, especially in today’s economic climate," noted Mike Soenen, Managing Partner of ClearTrial. "The pressure to move faster with fewer resources has never been greater and with Portfolio Planning, ClearTrial is again first in class to answer that challenge." Key Benefits of ClearTrial Portfolio Planning Integrated Roll-up for Increased Accuracy and Speed – The software eliminates errors in the time-consuming re-keying involved with manually rolling up multiple study plans into program- or company-wide forecasts. ClearTrial Portfolio Planning also ensures that planners are using the most current information by automatically updating the portfolio forecast with any changes made to the protocol-level assumptions. Effortless Cost and Resource Demand Forecasting Across the Organization – Monthly cost and resource demand forecasts enable companies to easily identify areas of heavy FTE utilization, and more proactively hire or contract for additional resources – or modify study start dates to smooth out resource utilization. Planners can instantly see the budget and resource impact of dropping or delaying a study or group of studies, immediately assess the result on hours and fees, by month, of outsourcing all monitoring, and more. Flexibility to Support Business Objectives and Processes – ClearTrial Portfolio Planning enables the creation of portfolios along any clinical development dimension to:
“With version 2.7, ClearTrial continues to set the standard for clinical software that helps life sciences companies bring new, quality treatments to market more rapidly," Soenen stated. "We're pleased to introduce this much-needed capability to the benefit of the industry." About ClearTrial® ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners. For more information contact: Mike Lange |
